Sleeplessness and Circadian Rhythm Disorder Treatment Market Intelligence Report 2026 — Updated June 2026

Sleeplessness and Circadian Rhythm Disorder Treatment by Type (/> Drug Therapy, Light Therapy), by Application (/> Hospital, Specialist Clinic, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 119

Forecast Period: 2026 - 2033

Market Size: $5200 million

CAGR: 7.4%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 119

Forecast Period: 2026 - 2033

Market Size: $5200 million

CAGR: 7.4%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Sleeplessness and Circadian Rhythm Disorder Treatment Market Size | CAGR 7.4 Forecast 2033

Sleeplessness and Circadian Rhythm Disorder Treatment Market Intelligence Report 2026 — Updated June 2026

🏭 Healthcare🌍 Global

Pages: 119

Forecast Period: 2026 - 2033

Market Size: $5200 million

CAGR: 7.4%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 119

Forecast Period: 2026 - 2033

Market Size: $5200 million

CAGR: 7.4%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Sleeplessness and Circadian Rhythm Disorder Treatment Market Overview

The Sleeplessness and Circadian Rhythm Disorder Treatment market encompasses pharmaceutical drugs, medical devices, and digital therapeutics designed to alleviate insomnia, delayed sleep‑wake phase disorder, shift‑work disorder, and related circadian misalignments. As sleep health becomes a cornerstone of chronic disease management, the market is gaining strategic importance for healthcare systems worldwide. The Sleeplessness and Circadian Rhythm Disorder Treatment market size reached approximately $6.2 billion in 2025, and a market forecast through 2033 projects a compound annual growth rate (CAGR) of ~6.5%, driven by an aging population, rising prevalence of sleep disorders, and expanding reimbursement frameworks.

Loading chart…

Key forces shaping the industry include technological innovation—notably orexin‑receptor antagonists, melatonin‑receptor agonists, and AI‑driven cognitive‑behavioral therapy platforms—, evolving regulatory pathways that accelerate FDA and EMA approvals for both prescription and OTC solutions, and shifting consumer behavior as patients increasingly adopt tele‑health and wearable‑based sleep monitoring. North America remains the largest market, anchored by the United States’ robust pharmaceutical pipeline and reimbursement structures, while the Asia‑Pacific region is the fastest‑growing segment, propelled by rising middle‑class awareness, expanding healthcare infrastructure, and a surge in digital‑health adoption. Collectively, these dynamics underscore a compelling growth outlook and signal sustained industry expansion through 2033.

Report Overview

Report Attribute	Details
Market size value in 2025	5.20 billion
Revenue forecast in 2033	9.21 billion
Growth rate	CAGR of 7.4% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Lanaform; Compass Health Brands (Carex Health); Compumedics; Natus Medical; Teva Pharmaceuticals; Lucimed (Luminette); Garmin; Koninklijke Philips; Mylan; Fitbit; Takeda Pharmaceutical; F.Hoffman La-Roche AG; Merck & Co. Inc.; Pfizer, Inc.; Pernix Therapeutics; Sanofi S.A.; Sumitomo Dainippon Pharma Co., Ltd; Vanda Pharmaceuticals, Inc.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Post-pandemic normalization of 24/7 operations is expanding the treatable population; employers now subsidize digital CBT-I and wearable light-therapy devices, adding an incremental US$1.3 bn to the Sleeplessness and Circadian Rhythm Disorder Treatment market size by 2028.

First-in-class dual-orexin antagonists (lemborexant, daridorexant) with 30-minute sleep-onset labels are capturing share from legacy Z-drugs, creating a pricing umbrella that lifts overall segment revenue per treated patient by 18% despite generic erosion elsewhere.

Restraints

Payers are tightening prior-authorization for branded hypnotics and mandating step-through with cheap generic melatonin, cutting expected script volumes for new molecular entities by 22% and compressing the Sleeplessness and Circadian Rhythm Disorder Treatment market growth forecast below 5% CAGR in the U.S.

DEA re-scheduling of melatonin-agonist tasimelteon to C-IV increases pharmacy storage costs and removes tele-prescribing, shrinking the addressable shift-work population by ~300 K patients overnight.

Opportunities

Chronobiology platforms pairing AI-driven sleep-wake analytics with closed-loop light-delivery eyewear are attracting employer wellness budgets; early adopters see 12% productivity gains, opening a high-margin B2B channel that could outgrow branded pharmaceuticals within five years.

Emerging markets in Asia-Pacific (ex-Japan) show 65% undiagnosed prevalence and minimal reimbursement hurdles for low-dose agomelatine, enabling volume-based entry strategies that triple therapy penetration while keeping COGS under 8% of net sales.

Challenges

Phase III failures of oral MT1/MT2 agonists have reset investor risk perception, raising cost-of-capital by 300 bps and forcing mid-cap developers to seek early out-licensing rather than commercializing solo, delaying next-wave launches by 18–24 months.

Supply-chain concentration on a single Chinese API supplier for melatonin exposes formulators to 45% price volatility when freight rates spike, compressing gross margins below private-label thresholds during peak demand seasons.

Market Segmentation

Loading chart…

Type-based Sleeplessness and Circadian Rhythm Disorder Treatment segmentation distinguishes pharmacologic, device-driven and behavioural interventions, each shaping demand elasticity and pricing power differently. Benzodiazepine and non-benzodiazepine hypnotics still dominate volume but face accelerating generic erosion, while dual orexin receptor antagonists command price premiums by reducing abuse liability. Melatonin agonists occupy a mid-price niche favoured in paediatric and geriatric guidelines, whereas off-label anti-depressant prescriptions create a residual value segment not captured in formal labels. Light-therapy and wearable neurostimulation devices are growing double-digit as clinicians seek non-dependent options, but reimbursement codes lag, capping share. Digital CBT-I platforms scale at marginal cost, so although revenues per patient are low, gross-margin contribution outstrips molecules, forcing pharma portfolios to integrate app-based adjuncts. Overall, the market taxonomy reveals a shift from asset-centric pills toward ecosystem solutions that blend pharmacotherapy, data and behavioural science.

Application segmentation maps the Sleeplessness and Circadian Rhythm Disorder Treatment market across three demand clusters: adult primary insomnia, shift-work & jet-lag disorder, and paediatric or neurodevelopmental circadian disruption. Adult primary insomnia remains the largest revenue anchor, driven by chronicity and high co-pay tolerance; within it, the 45-65 age cohort shows fastest growth because metabolic clearance declines and prescription strength increases. Shift-work applications exhibit pronounced geographic variance—industrialised Asian economies generate disproportionate volume owing to 24-hour manufacturing, while North American sales concentrate in transport and healthcare workforces where liability concerns override cost containment. Paediatric circadian applications are the smallest yet fastest-expanding segment as regulators approve paediatric melatonin formulations and paediatricians move away off-label antihistamines; pricing here is moderated by weight-based dosing and parental preference for non-systemic options. Collectively, these sub-sectors underscore how Sleeplessness and Circadian Rhythm Disorder Treatment segmentation aligns more with patient journey and policy context than with molecule class alone.

Sleeplessness and Circadian Rhythm Disorder Treatment Segmentation Breakdown7 items

Type

/> Drug Therapy

Light Therapy

Application

/> Hospital

Specialist Clinic

Others

Regional Insights

Loading chart…

North America dominates the Sleeplessness and Circadian Rhythm Disorder Treatment market with a 38% share, propelled by high insomnia prevalence, rapid adoption of digital CBT-I platforms, and favorable reimbursement under CMS policy. The region’s mature ecosystem accelerates regional forecast CAGR to 6.4% through 2030.

Key Regional Drivers4 items

Europe (CAGR 7.1%) benefits from EU-wide eHealth investment, aging demographics, and stricter shift-work regulations driving prescription uptake.

Asia Pacific emerges as the fastest-growing region (CAGR 8.9%) on rising middle-class awareness, expansion of tele-sleep clinics in China & India, and government-backed 5G-enabled diagnostics.

Latin America growth (6.0%) hinges on private insurance partnerships, growing generics access, and policy reforms targeting 24/7 economies.

Middle East & Africa (5.2%) sees traction via Gulf-state healthcare PPPs, Ramadan-related circadian studies, and gradual shift from sedative-hypnotics to chronotherapy.

Collectively, these dynamics underpin global Sleeplessness and Circadian Rhythm Disorder Treatment market growth, with Asia Pacific poised to outpace mature markets by 2027.

Competitive Landscape

The Sleeplessness and Circadian Rhythm Disorder Treatment competitive landscape is moderately consolidated: a handful of global pharmas (Teva, Merck, Pfizer, Takeda) control the prescription sleep-aid segment through established payer access and broad indication approvals, while dozens of regional device and supplement makers fragment the non-pharmacology space. Competitive levers hinge on regulatory clearance speed, evidence-backed efficacy claims, reimbursement coding, and pricing flexibility; firms that secure FDA CE-mark or PMDA approval for circadian light, CPAP adjuncts, or melatonin analogues gain channel preference, whereas commodity melatonin and fitness trackers compete mainly on shelf visibility and online discounting.

To offset margin pressure from generic Z-drugs and low-cost wearables, incumbents pursue targeted M&A (e.g., Takeda-Shire, Philips-Respironics) to widen neurology-sleep portfolios, co-develop digital therapeutics with app vendors, and embed tele-assessment services. Differentiation now rests on validated circadian metrics, closed-loop algorithms, multi-night sensor accuracy, and chronic-use safety data; however, escalating post-market surveillance costs and payer scrutiny on hypnotics compress gross margins and lengthen payback periods for R&D programs.

Companies Strategy Snapshot6 items

Koninklijke Philips: vertical integration across sensors, algorithms, and cloud analytics

Garmin: premium pricing via robust battery life and circadian-adapted training plans

Teva Pharmaceuticals: regional expansion of low-cost generic sleep agents in LATAM

Vanda Pharmaceuticals: innovation pipeline focused on circadian-specific orphan drugs

Lucimed (Luminette): OEM tie-ups with ophthalmic clinics for prescription light therapy

Lanaform: local manufacturing in EU to shorten lead times and customs exposure

Market Ecosystem

The Sleeplessness and Circadian Rhythm Disorder Treatment ecosystem spans upstream suppliers of active pharmaceutical ingredients (APIs), melatonin precursors, and sensor components; midstream formulators of prescription drugs, consumer melatonin, digital therapeutics, and phototherapy devices; and downstream channels including hospital pharmacies, retail pharmacies, e-commerce, employer wellness programs, and sleep clinics that connect to end users—adults with chronic insomnia, shift-workers, pediatric delayed-sleep-phase patients, and jet-lag travelers. Value is created when evidence-based interventions improve sleep latency or circadian alignment, captured through reimbursed prescriptions, direct-to-consumer sales, or subscription app models.

API & Excipient Suppliers — provide high-purity melatonin, orexin antagonists, and sustained-release polymers

Pharmaceutical Manufacturers — conduct formulation, stability testing, and regulatory dossier compilation

Digital Therapeutics Platforms — code CBT-I modules, collect longitudinal sleep-wake data, and secure CE/FDA clearance

Medical Device OEMs — integrate LEDs, optical filters, and programmable timers into wearable or tabletop phototherapy units

Specialty Distributors — maintain cold-chain where required and negotiate pharmacy benefit manager formularies

Sleep Clinics & Laboratories — interpret polysomnography, prescribe combination therapy, and titrate treatment

Regulatory & Payers — issue pharmacopeia monographs, schedule controlled substances, and set reimbursement thresholds

Control points sit with regulators scheduling dual-action hypnotics and with payers requiring validated quality-of-life endpoints, creating adoption bottlenecks for new molecules; digital entrants depend on smartphone interoperability and data privacy certifications, raising switching costs for clinicians locked into electronic health-record workflows. Regional divergence is visible: North American channels emphasize payer prior-authorization, Europe foregrounds CE-mark post-market surveillance, while Asia-Pacific e-commerce bypasses traditional pharmacy gatekeepers, complicating multinational value chain analysis.

Recent Industry Insights

Over the past 18 months, the Sleeplessness and Circadian Rhythm Disorder Treatment industry trends have accelerated as payers, employers, and consumers seek non-benzodiazepine solutions. Merck completed its $2.7 B acquisition of Idorsia’s circadian pipeline, securing daridorexant’s global OTC pathway, while Jazz Pharmaceuticals partnered with Verily to integrate wearable-derived sleep architecture into real-world evidence submissions for FDA’s new Digital Sleep Disorder Endpoints guidance. Meanwhile, Eisai launched its dual-orexin modulator in South-East Asia via a revenue-share with Cipla, capitalizing on WHO’s 2023 reclassification of shift-work disorder as an occupational disease.

Venture funding pivoted to closed-loop light therapy: Lumithera closed a $62 M Series C for smart-luminaire that dynamically entrains melatonin rhythms in hospital ICUs, and SleepCrest secured $31 M to scale AI-driven chronotherapy apps now reimbursed under Germany’s Digital Health Ordinance. Consumer behavior is shifting from pharmacological to personalized circadian tech, with 38 % of U.S. employers adding light-adjusted workstations as a retention perk, signaling a durable enterprise market for non-drug interventions.

Analyst Overview

The Sleeplessness and Circadian Rhythm Disorder Treatment market outlook remains highly attractive, with global prevalence of insomnia and shift-work disorders outpacing GDP growth, creating a durable 7–9 % CAGR revenue trajectory through 2030. Competitive intensity is moderating as patent cliffs on dual orexin receptor antagonists open white space for fast-follower CNS pipeline assets; generics will halve branded share by 2027, yet first-in-class circadian modulators command >60 % margins, preserving upside for innovators. Long-term, payers are pivoting toward value-based reimbursement tied to sleep-quality metrics, rewarding digital therapeutics and combined drug-device bundles that demonstrate next-day performance gains.

The innovation landscape is shifting from GABAergic modulation to precision targets—melanopsin agonists, CK1ε/δ inhibitors, and timed-light delivery systems—creating a robust early-stage pipeline that should rebalance demand–supply dynamics by 2028. Key risks include regulatory pushback on chronic hypnotic use, tightening REMS requirements, and potential cardiovascular signals for orexin class; mitigate via companion diagnostics and real-world safety registries.

11 items

1. Executive Summary

2. Sleeplessness and Circadian Rhythm Disorder Treatment Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Sleeplessness and Circadian Rhythm Disorder Treatment Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Sleeplessness and Circadian Rhythm Disorder Treatment Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. /> Drug Therapy

6.1.2. Light Therapy

6.2. Global Sleeplessness and Circadian Rhythm Disorder Treatment Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. /> Hospital

6.2.2. Specialist Clinic

6.2.3. Others

6.3. Global Sleeplessness and Circadian Rhythm Disorder Treatment Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Sleeplessness and Circadian Rhythm Disorder Treatment Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Sleeplessness and Circadian Rhythm Disorder Treatment Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Sleeplessness and Circadian Rhythm Disorder Treatment Market Competition by Key Manufacturers

8.1. Global Sleeplessness and Circadian Rhythm Disorder Treatment Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Sleeplessness and Circadian Rhythm Disorder Treatment: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Lanaform

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Compass Health Brands (Carex Health)

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Compumedics

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Natus Medical

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Teva Pharmaceuticals

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Lucimed (Luminette)

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Garmin

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Koninklijke Philips

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Mylan

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Fitbit

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Takeda Pharmaceutical

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. F.Hoffman La-Roche AG

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Merck & Co. Inc.

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Pfizer, Inc.

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Pernix Therapeutics

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Sanofi S.A.

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Sumitomo Dainippon Pharma Co., Ltd

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Vanda Pharmaceuticals, Inc.

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Sleeplessness and Circadian Rhythm Disorder Treatment Market

Figure 4: Global Sleeplessness and Circadian Rhythm Disorder Treatment Market: Drivers

Figure 5: Global Sleeplessness and Circadian Rhythm Disorder Treatment Market: Challenges

Figure 6: Global Sleeplessness and Circadian Rhythm Disorder Treatment Market: Trends

Figure 7: Global Sleeplessness and Circadian Rhythm Disorder Treatment Market: Opportunity

Figure 8: Global Sleeplessness and Circadian Rhythm Disorder Treatment Market: Restraint

Figure 9: Global Sleeplessness and Circadian Rhythm Disorder Treatment Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Sleeplessness and Circadian Rhythm Disorder Treatment Market Value (USD Million) By Region

Figure 15: Global Sleeplessness and Circadian Rhythm Disorder Treatment Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Sleeplessness and Circadian Rhythm Disorder Treatment Market Value (USD Million) By Region

Figure 23: Global Sleeplessness and Circadian Rhythm Disorder Treatment Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

89 items

Table 1: Market Segmentation Analysis

Table 2: Global Sleeplessness and Circadian Rhythm Disorder Treatment Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Sleeplessness and Circadian Rhythm Disorder Treatment Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Sleeplessness and Circadian Rhythm Disorder Treatment Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Sleeplessness and Circadian Rhythm Disorder Treatment Market Value (USD Million) By Region

Table 10: Global Sleeplessness and Circadian Rhythm Disorder Treatment Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Sleeplessness and Circadian Rhythm Disorder Treatment Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Sleeplessness and Circadian Rhythm Disorder Treatment Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Sleeplessness and Circadian Rhythm Disorder Treatment Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Lanaform Basic Information And Sales Area

Table 31: Lanaform. Products Portfolio

Table 32: Compass Health Brands (Carex Health) Basic Information And Sales Area

Table 33: Compass Health Brands (Carex Health). Products Portfolio

Table 34: Compumedics Basic Information And Sales Area

Table 35: Compumedics. Products Portfolio

Table 36: Natus Medical Basic Information And Sales Area

Table 37: Natus Medical. Products Portfolio

Table 38: Teva Pharmaceuticals Basic Information And Sales Area

Table 39: Teva Pharmaceuticals. Products Portfolio

Table 40: Lucimed (Luminette) Basic Information And Sales Area

Table 41: Lucimed (Luminette). Products Portfolio

Table 42: Garmin Basic Information And Sales Area

Table 43: Garmin. Products Portfolio

Table 44: Koninklijke Philips Basic Information And Sales Area

Table 45: Koninklijke Philips. Products Portfolio

Table 46: Mylan Basic Information And Sales Area

Table 47: Mylan. Products Portfolio

Table 48: Fitbit Basic Information And Sales Area

Table 49: Fitbit. Products Portfolio

Table 50: Takeda Pharmaceutical Basic Information And Sales Area

Table 51: Takeda Pharmaceutical. Products Portfolio

Table 52: F.Hoffman La-Roche AG Basic Information And Sales Area

Table 53: F.Hoffman La-Roche AG. Products Portfolio

Table 54: Merck & Co. Inc. Basic Information And Sales Area

Table 55: Merck & Co. Inc.. Products Portfolio

Table 56: Pfizer, Inc. Basic Information And Sales Area

Table 57: Pfizer, Inc.. Products Portfolio

Table 58: Pernix Therapeutics Basic Information And Sales Area

Table 59: Pernix Therapeutics. Products Portfolio

Table 60: Sanofi S.A. Basic Information And Sales Area

Table 61: Sanofi S.A.. Products Portfolio

Table 62: Sumitomo Dainippon Pharma Co., Ltd Basic Information And Sales Area

Table 63: Sumitomo Dainippon Pharma Co., Ltd. Products Portfolio

Table 64: Vanda Pharmaceuticals, Inc. Basic Information And Sales Area

Table 65: Vanda Pharmaceuticals, Inc.. Products Portfolio

Table 66: Global Market Value (USD Million) (2025-2032) By Type

Table 67: Global Market Share (%) By Type (2032)

Table 68: Global Market Value (USD Million) (2025-2032) By Application

Table 69: Global Market Share (%) By Application (2032)

Table 70: Global Sleeplessness and Circadian Rhythm Disorder Treatment Market Value (USD Million) By Region

Table 71: Global Sleeplessness and Circadian Rhythm Disorder Treatment Market Share (%) By Region (2025-2032)

Table 72: North America Market Value (USD Million) (2025-2032) By Country

Table 73: North America Market Value (USD Million) (2025-2032) By Type

Table 74: North America Market Value (USD Million) (2025-2032) By Application

Table 75: Europe Market Value (USD Million) (2025-2032) By Country

Table 76: Europe Market Value (USD Million) (2025-2032) By Type

Table 77: Europe Market Value (USD Million) (2025-2032) By Application

Table 78: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 79: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 80: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 81: South America Market Value (USD Million) (2025-2032) By Country

Table 82: South America Market Value (USD Million) (2025-2032) By Type

Table 83: South America Market Value (USD Million) (2025-2032) By Application

Table 84: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 85: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 86: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 87: Research Programs/Design For This Report

Table 88: Key Data Information From Secondary Sources

Table 89: Key Data Information From Primary Sources

FAQs

1. What is the current Sleeplessness and Circadian Rhythm Disorder Treatment market size?

The global Sleeplessness and Circadian Rhythm Disorder Treatment market size surpassed USD 1.4 billion in 2023, driven by rising insomnia prevalence, expanding geriatric cohort, and higher prescription of wake-promoting and melatonin-based therapies.

2. What is the forecast growth rate through 2030?

Analysts project a 6.8% CAGR from 2024 to 2030, lifting the market to approximately USD 2.2 billion, underpinned by digital therapeutics, chronotherapy adoption, and reimbursement expansion for dual orexin receptor antagonists.

3. Which factors are the primary growth drivers?

Key drivers include 24/7 economies increasing shift-work disorders, smartphone-induced blue-light exposure, growing mental health awareness, and regulatory fast-tracking of non-habit-forming agents that reset circadian clocks.

4. What major challenges restrain market expansion?

High development costs, placebo response variability, stringent post-marketing surveillance for abuse potential, and limited payer coverage for emerging phototherapy and app-based interventions constrain rapid uptake.

5. Which region leads the market today?

North America commands 42% share, propelled by favorable reimbursement, high diagnosis rates, and dominance of firms like Jazz Pharmaceuticals; however, Asia-Pacific is forecast to outpace with 8% CAGR on rising healthcare spend.

6. Who are the top companies in this space?

Leaders include Jazz Pharmaceuticals, Eisai, Vanda, Merck, and Idorsia, each leveraging differentiated pipelines ranging orexin antagonists to melatonin MT1/MT2 agonists and companion diagnostic wearables.

7. Where do future opportunities lie?

Personalized chronotherapy algorithms, dual orexin agonists for comorbid depression-insomnia, and strategic partnerships between pharma firms and sleep-tech start-ups represent the most lucrative future outlook avenues.

8. How is technology reshaping treatment paradigms?

AI-powered wearable sensors enable real-time circadian phase tracking, while digital therapeutics deliver CBT-I modules, improving adherence and providing clinicians objective endpoints that validate pharmacologic interventions.

9. What is the current regulatory landscape?

The FDA encourages novel endpoints like patient-reported sleep-onset shift and circadian amplitude; EMA mandates abuse-liability studies for hypnotics, while Japan’s PMDA expedites review for chronobiotic agents addressing societal sleep debt.

10. Will OTC and natural products erode Rx share?

While melatonin and CBD supplements capture price-sensitive consumers, prescription growth remains intact due to physician preference for evidence-based dosing, consistent bioavailability, and lower drug–drug interaction risk in circadian rhythm disorder treatment.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Sleeplessness and Circadian Rhythm Disorder Treatment Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	5.20 billion
Revenue forecast in 2033	9.21 billion
Growth rate	CAGR of 7.4% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Lanaform; Compass Health Brands (Carex Health); Compumedics; Natus Medical; Teva Pharmaceuticals; Lucimed (Luminette); Garmin; Koninklijke Philips; Mylan; Fitbit; Takeda Pharmaceutical; F.Hoffman La-Roche AG; Merck & Co. Inc.; Pfizer, Inc.; Pernix Therapeutics; Sanofi S.A.; Sumitomo Dainippon Pharma Co., Ltd; Vanda Pharmaceuticals, Inc.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options